Week in Review • INTELLIGENCE BRIEF • May 9, 2026

TOP STORIES

Novo's oral Wegovy captures $355M in first quarter — pricing strategy pressures Lilly's Foundayo launch trajectory

Novo Nordisk reported $355 million in first-quarter sales for oral Wegovy and raised its full-year guidance, crediting a 'pricing sweet spot' as a competitive advantage against Eli Lilly in the oral obesity market, per Fierce Pharma. The Danish company's three-month head start over Lilly's Foundayo (orforglipron, approved April 1, 2026) has translated into substantial early commercial traction. Prescription volume exceeded company projections, prompting Novo to narrow expected revenue and operating profit declines for the full year, according to the Q1 2026 earnings report. CEO Lars Fruergaard Jørgensen described the oral formulation's pricing strategy as differentiated, suggesting Novo is attempting to capture share before Lilly's entry while maintaining premium economics relative to injectable versions.

Competitive implications: Eli Lilly faces pricing pressure as Foundayo (orforglipron), approved April 1 and launched April 6, enters a market where Novo has already established commercial traction, potentially forcing more aggressive launch economics or accelerated real-world evidence generation to demonstrate superior weight loss versus oral semaglutide. Roche's oral GLP-1 candidates and other late-stage competitors must now clear a higher bar for differentiation as Novo establishes early oral market presence with proven prescription volume. Injectable GLP-1 franchises—including Lilly's Zepbound and Novo's injectable Wegovy—may face accelerated erosion if oral formulations demonstrate comparable efficacy with improved adherence. The pricing 'sweet spot' Novo claims suggests it is maintaining premium economics while undercutting Foundayo and future oral competitors, creating a narrow window for Lilly to establish differentiated value on efficacy or dosing convenience.

Key risks: Lilly could pursue aggressive payer contracting, combination strategies, or a diabetes-indication filing for Foundayo to offset Novo's head start in obesity. Long-term comparative efficacy data between oral and injectable GLP-1 formulations remain limited, and any safety signals in expanded real-world use could alter market dynamics for both oral programs.

Daiichi Sankyo writes off $950M in ADC capacity — overcommitment precedent raises scrutiny for rivals' capex plans

Daiichi Sankyo recorded a 149.4 billion yen ($950 million) extraordinary loss after canceling internal ADC manufacturing expansion plans, having overcommitted to third-party contract manufacturers based on demand projections that did not materialize, per Endpoints News. The writedown reflects a near-billion-dollar strategic misjudgment in capacity planning for the company's ADC portfolio, forcing reassessment of capital allocation strategy. Fierce Pharma separately reported a $610 million profit impact linked to the ADC manufacturing losses, a figure that may reflect operating profit rather than the full extraordinary charge, per Fierce Pharma. The company did not disclose whether the overcapacity stems from slower-than-expected uptake of approved products like Enhertu or delayed timelines for pipeline ADCs.

Competitive implications: Other ADC developers with large manufacturing commitments—including AbbVie, Pfizer, Gilead, and Merck—may face heightened investor questioning on capacity utilization rates and demand assumptions underlying capex decisions. Companies pursuing internal manufacturing versus contract relationships must now justify their approach against Daiichi's costly reversal of expansion plans. The writedown may embolden contract manufacturers to negotiate more favorable terms with biotech and pharma clients wary of overcommitting to internal capacity. Investors in ADC-focused biotechs will likely demand more conservative capacity planning and phased expansion strategies tied to validated commercial milestones rather than optimistic peak sales projections.

Key risks: If Daiichi's ADC portfolio subsequently demonstrates stronger uptake than current capacity supports, the company may face supply constraints and lost revenue. The decision to cancel internal expansion could leave Daiichi reliant on third-party manufacturers with limited flexibility to scale production rapidly.

Bayer commits $2.45B for Perfuse's glaucoma asset — largest drug M&A since 2020 signals ophthalmology buildout

Bayer will pay up to $2.45 billion to acquire Perfuse Therapeutics and its Phase 2 glaucoma therapy, marking the company's largest drug acquisition since the $4.1 billion AskBio deal in 2020, per BioPharma Dive. The transaction includes $300 million upfront and up to $2.15 billion in milestones, according to Fierce Biotech. Perfuse's implant showed improved outcomes in two Phase 2 trials in 2025, positioning Bayer to compete in the primary open-angle glaucoma market currently dominated by topical prostaglandin analogs and combination therapies. The deal bolsters Bayer's ophthalmology pipeline, which includes Eylea biosimilar commercialization rights ex-US and acquired SparingVision gene therapy programs.

Competitive implications: Regeneron, Bayer's Eylea partner, and other ophthalmology players including Roche/Genentech will watch whether the implant technology can compete with established anti-VEGF therapies or address unmet needs in retinal diseases beyond glaucoma. The acquisition may accelerate consolidation in ophthalmic delivery technologies as large pharmas seek to differentiate aging franchises through novel formulations and administration methods. Companies with sustained-release or implantable drug delivery platforms could see increased M&A interest if Bayer's bet validates investor appetite for device-drug combinations in chronic eye diseases. The size of the commitment—Bayer's largest in six years—signals management confidence in ophthalmology as a durable growth area despite competitive pressures in anti-VEGF markets.

Key risks: The Phase 2 data for Perfuse's implant have not been publicly disclosed in detail, leaving uncertainty about the asset's competitive profile versus existing glaucoma therapies. The milestone-heavy deal structure exposes Bayer to risk if pivotal trials fail to replicate Phase 2 results or if regulatory approval timelines extend.

REGULATORY & APPROVALS

• Sanofi requested withdrawal of its Tzield application from FDA's Commissioner's National Priority Voucher pilot program after CDER director Tracy Beth Høeg reportedly overturned a staff decision on the application, citing concerns including Epstein-Barr virus and cancer risk, per Fierce Pharma. The voluntary exit reflects growing industry unease with the controversial program's governance and unpredictable decision-making. Other companies with CNPV applications may reassess whether expedited timelines offset risks to product credibility and payer acceptance.
• Atara Biotherapeutics and Pierre Fabre secured FDA agreement to reconsider their Phase 3 EBV T-cell therapy data as the basis for approval after two prior rejections, per Endpoints News. The rare reversal on a twice-rejected program signals potential FDA flexibility on evidentiary standards for rare post-transplant lymphoproliferative disease.
• The Supreme Court issued a temporary stay on May 4 (Justice Alito, expiring May 11) restoring online access to mifepristone following the 5th Circuit's May 1 decision restricting telemedicine prescribing, with the case potentially establishing precedent for FDA authority over drug distribution channels beyond abortion, per Fierce Pharma.

CLINICAL DATA

• EnGene Therapeutics' stock fell 80% following updated Phase 2 bladder cancer data that widened the efficacy gap versus Johnson & Johnson's competing asset, prompting Leerink Partners to lower peak sales projections, per Fierce Biotech.
• Novo Nordisk terminated development of a single-chamber delivery device for CagriSema (semaglutide/cagrilintide combination) but stated the launch timeline remains unchanged, per Fierce Biotech. Technical reasons for the device termination were not disclosed.
• BeOne Medicines terminated five Phase 1 oncology programs and discontinued a Phase 2 rheumatoid arthritis trial based on newly available data, representing a strategic contraction of the company's early-stage pipeline, per Fierce Biotech.

DEALS & PARTNERSHIPS

• Italian pharma Angelini is acquiring Catalyst Pharmaceuticals for $4.1 billion to secure a portfolio of approved CNS disorder treatments and expanded US commercial infrastructure, per BioPharma Dive.
• Blackstone Life Sciences committed $250 million to Anagram Therapeutics to develop a three-pill daily regimen for exocrine pancreatic insufficiency in cystic fibrosis patients, who currently take up to 40 pancreatic enzyme replacement pills daily, per Fierce Biotech.
• Ipsen discontinued both liver disease candidates acquired from Albireo in 2023, writing off the $952 million transaction within two years, per Fierce Biotech.
• CellCentric closed a $220 million series D to fund its myeloma candidate through registration trials and potential market launch, marking a strategic pivot from seeking pharma partnerships to independent commercialization, per Fierce Biotech.

BUSINESS & FINANCE

• Odyssey Therapeutics closed a $304 million IPO, pricing above initial expectations in a market where biotech offerings remain scarce, with the upsized offering suggesting investor appetite for differentiated platform stories in autoimmune indications, per Fierce Biotech.
• Amgen and AbbVie disclosed that the first negotiated drug prices under the Inflation Reduction Act, which took effect in January 2026, reduced first-quarter sales, marking the first reported financial impact from the program, per Endpoints News.
• Eli Lilly will invest $4.5 billion in new manufacturing capacity across Indiana, marking the latest in a wave of domestic production commitments by major drugmakers amid supply chain and policy pressures, per Endpoints News.
• Recursion Pharmaceuticals' CEO Najat Khan, Ph.D., who replaced founder Chris Gibson in November 2025, outlined a shift toward product delivery over AI platform promises in a recent interview, with Khan's strategic pivot drawing renewed investor attention six months into her tenure, per Fierce Biotech.

WHAT TO WATCH NEXT

Foundayo's commercial ramp will test Lilly's pricing strategy against Novo's oral Wegovy head start

Eli Lilly's Foundayo (orforglipron), approved April 1 and launched April 6, faces heightened commercial expectations following Novo Nordisk's $355 million first-quarter oral Wegovy sales and 'pricing sweet spot' positioning, per Fierce Pharma. Foundayo's no-food/water-restriction dosing advantage must translate to payer preference and prescription volume against oral Wegovy's three-month head start. Lilly's Q2 earnings, expected in late July, will provide the first direct commercial comparison between the two oral obesity therapies and could reshape investor expectations for the broader oral GLP-1 category.

Supreme Court mifepristone ruling could establish FDA distribution authority precedent

The Supreme Court's review of mifepristone telemedicine access could establish precedent for FDA authority over drug distribution channels and telemedicine prescribing frameworks across therapeutic areas beyond abortion, per Fierce Pharma. A decision narrowing FDA distribution authority may affect online prescription drug access models industrywide, while upholding current frameworks would validate telemedicine pharmacy platforms' regulatory approach. The ruling could influence how digital health companies structure medication delivery and prescribing models.

CagriSema device setback tests Novo's dual-agonist differentiation strategy

Novo Nordisk terminated development of a single-chamber delivery device for CagriSema but maintains its launch timeline, potentially forcing a return to dual-chamber or multi-step administration that could complicate adherence versus competitors' single-injection formulations, per Fierce Biotech. The company has not disclosed technical reasons for device termination or revised regulatory filing timelines. CagriSema's superior weight loss versus semaglutide monotherapy in Phase 3 trials may be offset by convenience disadvantages if multi-step dosing is required, narrowing differentiation against Lilly's tirzepatide.